|Post IPO Valuation|
|Description||Biotech focused on BPH treatment|
|Partial Close, 4/2010 ||$226k|
|Venture Round, 9/2010 |
Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied patient population with significant market potential. Sophiris is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is currently in Phase 3 clinical development with a blinded interim analysis expected in the second half of 2014 followed by a complete data analysis in the second half of 2015. For more information, please visit www.sophiris.com.